Eli Lilly, Boehringer Diabetes Drug Faces FDA Roadblock

Law360, New York (March 5, 2014, 5:35 PM EST) -- The U.S. Food and Drug Administration has said it observed “deficiencies” at the site where a new diabetes drug developed by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. will be made, the companies said Wednesday, a potential roadblock to the drug’s approval.

The FDA replied to Boehringer and Eli Lilly's new drug application with a complete response letter that said it had seen problems at the facility where the Type 2 diabetes drug empagliflozin will be manufactured, the companies said. The FDA letter told...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.